199 related articles for article (PubMed ID: 11775044)
1. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?
Bloch Y; Mendlovic S; Strupinsky S; Altshuler A; Fennig S; Ratzoni G
J Clin Psychiatry; 2001 Nov; 62(11):855-9. PubMed ID: 11775044
[TBL] [Abstract][Full Text] [Related]
2. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
Atkins S; Detke HC; McDonnell DP; Case MG; Wang S
BMC Psychiatry; 2014 Jan; 14():7. PubMed ID: 24423017
[TBL] [Abstract][Full Text] [Related]
3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
4. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.
Valenstein M; Copeland LA; Owen R; Blow FC; Visnic S
J Clin Psychiatry; 2001 Jul; 62(7):545-51. PubMed ID: 11488366
[TBL] [Abstract][Full Text] [Related]
5. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral.
Patel MX; de Zoysa N; Bernadt M; David AS
J Clin Psychiatry; 2008 Oct; 69(10):1548-56. PubMed ID: 19192437
[TBL] [Abstract][Full Text] [Related]
6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
7. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
[TBL] [Abstract][Full Text] [Related]
8. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study].
Romain JL; Dermain P; Greslé P; Grignon S; Moisan P; Nore D; Pech G; Benyaya J; Perret I
Encephale; 1996; 22(4):280-6. PubMed ID: 9035983
[TBL] [Abstract][Full Text] [Related]
10. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
11. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
12. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
Quraishi S; David A
Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
[TBL] [Abstract][Full Text] [Related]
13. Use of topical application of lidocaine-prilocaine cream to reduce injection-site pain of depot antipsychotics.
Bloch Y; Levkovitz Y; Atshuler A; Dvoretzki V; Fenning S; Ratzoni G
Psychiatr Serv; 2004 Aug; 55(8):940-1. PubMed ID: 15292547
[TBL] [Abstract][Full Text] [Related]
14. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
15. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study.
Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG
Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481
[No Abstract] [Full Text] [Related]
16. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
Morrissette DA; Stahl SM
CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
[TBL] [Abstract][Full Text] [Related]
17. Long-term depot antipsychotics. A risk-benefit assessment.
Barnes TR; Curson DA
Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
[TBL] [Abstract][Full Text] [Related]
18. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
[TBL] [Abstract][Full Text] [Related]
19. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
Taylor DM; Young CL; Mace S; Patel MX
J Clin Psychiatry; 2004 Aug; 65(8):1076-83. PubMed ID: 15323592
[TBL] [Abstract][Full Text] [Related]
20. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
